Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis

Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis

Professional society guidelines recommend semiannual screening for hepatocellular carcinoma (HCC) in patients with cirrhosis; however, studies suggest underuse of screening in clinical practice. Our study’s aim was to characterize reasons for HCC screening underuse among patients with cirrhosis. We...

Full description

Bibliographic Details
Main Authors:	Patrick Marquardt, Po‐Hong Liu, Joshua Immergluck, Jocelyn Olivares, Ana Arroyo, Nicole E. Rich, Neehar D. Parikh, Adam C. Yopp, Amit G. Singal
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2021-09-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1735

Similar Items

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma.
by: Neehar D Parikh, et al.
Published: (2016-04-01)

A Biomarker Panel Based upon AFP, Fucosylated Kininogen and PEG-Precipitated IgG Is Highly Accurate for the Early Detection Hepatocellular Carcinoma in Patients with Cirrhosis in Phase II and Phase III Biomarker Evaluation
by: Mengjun Wang, et al.
Published: (2022-12-01)

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
by: Yi-Te Lee, et al.
Published: (2023-04-01)

A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation
by: Yu Lin, et al.
Published: (2022-03-01)

PRM-MS Quantitative Analysis of Isomeric <i>N</i>-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma
by: Cristian D. Gutierrez Reyes, et al.
Published: (2021-08-01)

Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.
by: Amit G Singal, et al.
Published: (2014-04-01)

Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
by: Mindie H. Nguyen, et al.
Published: (2022-12-01)

Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience
by: Michelle R. Ju, et al.
Published: (2020-05-01)

The Utility of Anatomical Liver Resection in Hepatocellular Carcinoma: Associated with Improved Outcomes or Lack of Supportive Evidence?
by: Michelle Ju, et al.
Published: (2019-09-01)

FIB-4 and APRI for cirrhosis detection in a privately insured national cohort
by: Neehar D. Parikh, et al.
Published: (2024-01-01)

Extrahepatic metastasis risk of hepatocellular carcinoma based on α-fetoprotein and tumor staging parameters at cross-sectional imaging
by: Yokoo T, et al.
Published: (2017-10-01)

Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis
by: Elliot B. Tapper, et al.
Published: (2022-06-01)

Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis
by: Amit G. Singal, et al.
Published: (2022-10-01)

Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma
by: Chen Hao Jiang, et al.
Published: (2020-01-01)

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
by: Andrew M. Brown, et al.
Published: (2023-02-01)

Comprehensive Health‐State Utilities in Contemporary Patients With Cirrhosis
by: Chelsey Foster, et al.
Published: (2020-06-01)

Diffuse infiltrative hepatocellular carcinoma or cirrhosis?
by: Jarosław Koza, et al.
Published: (2017-12-01)

Diffuse infiltrative hepatocellular carcinoma or cirrhosis?
by: Jarosław Koza, et al.
Published: (2017-12-01)

Angiogenesis in liver cirrhosis and hepatocellular carcinoma
by: Amarapurkar Anjali, et al.
Published: (2008-07-01)

A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk
by: Catherine T. Frenette, MD, et al.
Published: (2019-09-01)

Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcomes
by: Karlyn Martin, et al.
Published: (2014-09-01)

Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis
by: Alberto Zanetto, et al.
Published: (2021-03-01)

Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma
by: Nikita Sandeep Wagle, et al.
Published: (2022-05-01)

Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
by: Elliot B. Tapper, et al.
Published: (2019-11-01)

Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma
by: Zhaobin He, et al.
Published: (2022-03-01)

Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression
by: Michelle Junyi He, et al.
Published: (2022-11-01)

Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression
by: He, Michelle J., et al.
Published: (2022)

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.
by: Lauren Lapointe-Shaw, et al.
Published: (2018-01-01)

A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC
by: Roniel Cabrera, et al.
Published: (2021-03-01)

Screening for hepatocellular carcinoma
by: Jarosław Koza, et al.
Published: (2017-11-01)

Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer‐specific and overall mortality: A modeling approach
by: Massih Ningarhari, et al.
Published: (2022-10-01)

Screening for aberrantly methylated and differentially expressed genes in nonalcoholic fatty liver disease of hepatocellular carcinoma patients with cirrhosis
by: Guizhi Zhang, et al.
Published: (2022-11-01)

An Emphasis on Screening to Detect Liver Cirrhosis and Hepatocellular Carcinoma in Patients Having Undergone the Fontan Procedure in Early Childhood
by: Samragnyi Madala, et al.
Published: (2020-11-01)

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis
by: Hamish Innes, et al.
Published: (2022-05-01)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
by: Kazumichi Abe, et al.
Published: (2020-01-01)

Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
by: Marco Castellana, et al.
Published: (2021-10-01)

Identification reproducible microbiota biomarkers for the diagnosis of cirrhosis and hepatocellular carcinoma
by: Huarong Zhang, et al.
Published: (2023-03-01)

Microvessel Density and Clinicopathologic Characteristics in Hepatocellular Carcinoma With and Without Cirrhosis
by: Ivan Chebib, et al.
Published: (2007-01-01)

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis
by: J Thompson Coon, et al.
Published: (2007-09-01)

BIOCHEMICAL NUTRITIONAL PROFILE OF LIVER CIRRHOSIS PATIENTS WITH HEPATOCELLULAR CARCINOMA
by: Gabriela Zanatta PORT, et al.
Published: (2014-03-01)